Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Powles

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Cancer Treatment Reviews|June 10, 2021
Checkpoint inhibitors in metastatic papillary renal cell carcinomaM de Vries-Brilland, D F McDermott, C Suárez, et al.
British Journal of Cancer|October 13, 2006
The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumoursT Powles, A Young, A Sanitt, et al.
ESMO Open|June 30, 2026
Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapyT Powles, K Madjar, B I Balas, et al.
British Journal of Cancer|December 25, 2013
Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinomaN Bharwani, M E Miquel, T Powles, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancerB P Haynes, M Jarman, M Dowsett, et al.
British Journal of Cancer|February 3, 2011
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred DiethylstilbestrolJ Shamash, T Powles, S J Sarker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2003
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlationsJ Stebbing, A Wildfire, S Portsmouth, et al.
British Journal of Cancer|August 18, 2011
Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumourY Rimmer, J Chester, J Joffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2020
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trialsM Chalabi, A Cardona, D R Nagarkar, et al.
ESMO Open|February 26, 2026
Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trialJ Bedke, M S van der Heijden, G Sonpavde, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Cancer Treatment Reviews|June 10, 2021
Checkpoint inhibitors in metastatic papillary renal cell carcinomaM de Vries-Brilland, D F McDermott, C Suárez, et al.
British Journal of Cancer|October 13, 2006
The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumoursT Powles, A Young, A Sanitt, et al.
ESMO Open|June 30, 2026
Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapyT Powles, K Madjar, B I Balas, et al.
British Journal of Cancer|December 25, 2013
Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinomaN Bharwani, M E Miquel, T Powles, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancerB P Haynes, M Jarman, M Dowsett, et al.
British Journal of Cancer|February 3, 2011
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred DiethylstilbestrolJ Shamash, T Powles, S J Sarker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2003
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlationsJ Stebbing, A Wildfire, S Portsmouth, et al.
British Journal of Cancer|August 18, 2011
Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumourY Rimmer, J Chester, J Joffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2020
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trialsM Chalabi, A Cardona, D R Nagarkar, et al.
ESMO Open|February 26, 2026
Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trialJ Bedke, M S van der Heijden, G Sonpavde, et al.
Pageof 9